StreetAlpha.app
Home › Stocks › PMN

ProMIS Neurosciences Inc. (PMN)

$3.21
▼ −3.02%
LAST CLOSE · NOV 17

ProMIS Neurosciences develops antibody therapies that target harmful misfolded proteins in neurodegenerative diseases such as Alzheimer's. It last closed at $3.21 on Nov 17, down 3.02% on the day.

AI Auto Pilots
Is PMN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$38.8M
EPS (diluted)
−$6.42
Valuation
Market cap
$28.9M
9.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$44.1M
At Sep 30
Shareholder equity
$41.8M
Shares outstanding
9.0M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$9.8M−$9.8MFY2021FY2022: −$18.1M−$18.1MFY2022FY2023: −$13.2M−$13.2MFY2023FY2024: $2.8M$2.8MFY2024FY2025: −$39.7M−$39.7MFY2025

From PMN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PMN in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 367.3% upside

Based on 1 analyst who set a price target on PMN in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $3.21.

Low $15.00Avg $15.00High $15.00
Blue marker: last close $3.21
Highest target$15.00
Average target$15.00
Lowest target$15.00
Latest rating changes
Roth CapitalTarget lowered
Nov 2Buy$19 → $15
GuggenheimMaintained
Aug 14Buy$100
GuggenheimMaintained
Jul 29Buy$69
Chardan CapitalTarget raised
Jul 28Buy$20 → $33
Chardan CapitalInitiated
Jul 27Buy$20
DateFirmActionRatingPrice target
Nov 2Roth CapitalTarget loweredBuy$19 → $15
Aug 14GuggenheimMaintainedBuy$100
Jul 29GuggenheimMaintainedBuy$69
Jul 28Chardan CapitalTarget raisedBuy$20 → $33
Jul 27Chardan CapitalInitiatedBuy$20
Loading…

Technical Analysis

PMN · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 75% below its 20 day and 174% below its 50 day average. It is 289% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), near oversold. The nearest support is the Pivot S1 at $3.08, and the nearest resistance the Pivot at $3.23.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 29.1%/day
Key levels
$27.4052 week high+753.6%
$12.49200 day average+289.1%
$11.34100 day average+253.3%
$8.8050 day average+174.1%
$5.6120 day average+74.8%
$4.33Swing high (Nov 6)+34.9%
$3.37Pivot R1+5.0%
$3.23Pivot+0.6%
$3.21Last close
$3.08Pivot S1−4.0%
$2.7852 week low−13.4%
$2.78Swing low (Nov 2)−13.4%
Indicators
RSI (14)30.05Weak, oversold below 30Neutral
MACD-1.69Below its signal lineBearish
Stochastic5.5Near the bottom of its rangeOversold
ADX (14)32.5Trending down
Williams %R-95.0Oversold below −80, overbought above −20Oversold
CCI (20)-63.4Oversold below −100, overbought above 100Neutral
Rate of change−4.6%Change over 10 sessionsBearish
ATR (14)$0.93Typical daily range, 29.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PMN

What happened before

See how PMN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PMN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PMN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PMN in the last 90 days.

Loading…

See today’s whale options flow across the market →

PMN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 8 selling
  • ●Held by funds -0.4 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3127+14.8%
In funds' top 10220.0%
Held by funds70.8%71.2%−0.4 pts
New / increased7 / 44 / 70.0%
Reduced / sold out5 / 35 / 2+14.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PMN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMN is in one of them and how their past PMN trades turned out.

PMN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PMN in an article yet. Here's the latest on the wider market.

About ProMIS Neurosciences

ProMIS Neurosciences is a biotechnology company based in Toronto, Canada, that is developing antibody therapies for neurodegenerative diseases. Its main program targets Alzheimer's disease, and its other candidates address conditions such as ALS and Parkinson's disease. The company uses a computational platform to find targets that appear only on the harmful, misfolded form of a protein, so its antibodies aim to leave the healthy form alone. The therapies are intended for patients with these conditions, and the company is still in clinical development.

Headquarters
Toronto, Ontario, Canada